AHG
Akso Health·NASDAQ
--
--(--)
--
--(--)
0.97 / 10
Underperform
Financial analysis yields poor rating (1.0/10). Positive contributors: Net cash flow from operating activities / Total liabilities (%) and Interest coverage ratio (EBIT / Interest expense) (%), offset by weaknesses in Net cash flow from operating activities per share (YoY growth rate %) and Net cash flow from operating activities / Operating revenue (%). Concluding evaluation: defensive.
Analysis Checks(2/4)
Net cash flow from operating activities per share (YoY growth rate %)
Value-77.00
Score1/3
Weight27.57%
1M Return-3.23%
Value-77.00
Score1/3
Weight27.57%
1M Return-3.23%
Net cash flow from operating activities / Total liabilities (%)
Value0.07
Score2/3
Weight-4.95%
1M Return0.51%
Value0.07
Score2/3
Weight-4.95%
1M Return0.51%
Net cash flow from operating activities / Operating revenue (%)
Value7.97
Score0/3
Weight59.67%
1M Return-8.62%
Value7.97
Score0/3
Weight59.67%
1M Return-8.62%
Interest coverage ratio (EBIT / Interest expense) (%)
Value42.48
Score2/3
Weight17.71%
1M Return-2.02%
Value42.48
Score2/3
Weight17.71%
1M Return-2.02%
Net cash flow from operating activities per share (YoY growth rate %)
Value-77.00
Score1/3
Weight27.57%
1M Return-3.23%
Value-77.00
Score1/3
Weight27.57%
1M Return-3.23%
Net cash flow from operating activities / Operating revenue (%)
Value7.97
Score0/3
Weight59.67%
1M Return-8.62%
Value7.97
Score0/3
Weight59.67%
1M Return-8.62%
Net cash flow from operating activities / Total liabilities (%)
Value0.07
Score2/3
Weight-4.95%
1M Return0.51%
Value0.07
Score2/3
Weight-4.95%
1M Return0.51%
Interest coverage ratio (EBIT / Interest expense) (%)
Value42.48
Score2/3
Weight17.71%
1M Return-2.02%
Value42.48
Score2/3
Weight17.71%
1M Return-2.02%
Is AHG undervalued or overvalued?
- AHG scores 0.97/10 on fundamentals and holds a Premium valuation at present. Backed by its -79.97% ROE, -916.71% net margin, -6.09 P/E ratio, 4.13 P/B ratio, and -128.57% earnings growth, these metrics solidify its Underperform investment rating.
